Rheumatology

JAK inhibitors for RA: How do they stack up in real-world settings?

December 6, 2023

The efficacy and safety of tofacitinib, baricitinib, peficitinib or upadacitinib were not significantly different for the treatment of patients with rheumatoid arthritis in the ANSWER cohort study, which compared JAK inhibitor treatments among 622 patients in hospital settings across Japan.

• The 622 patients were selected from the ANSWER cohort database and treated with tofacitinib (TOFA), baricitinib (BARI), peficitinib (PEF), or upadacitinib (UPA).
• The patient's background was matched using propensity score-based inverse probability of treatment weighting among four treatment groups.
• Retention and discontinuation rates until 6 months after drug initiations were not significantly different among the four JAK inhibitors treatment groups.
• Mean Clinical Disease Activity Index (CDAI) value, CDAI remission rate, and CDAI-low disease activitiy rate at 6 months after drug initiation were not significantly different among treatment groups.
• Baseline CDAI (TOFA: OR 1.09, P < 0.001; BARI: OR 1.07, P < 0.001), baseline C-reactive protein (TOFA: OR 1.32, P = 0.049), baseline glucocorticoid dose (BARI: OR 1.18, 95% CI 1.01-1.38, P = 0.035), a number of previous biological or targeted synthetic disease-modifying antirheumatic drugs (biological/targeted synthetic DMARDs) (BARI: OR 1.36, P = 0.004) were predictive factors for resistance to CDAI-LDA achievement to JAK inhibitor treatment.

Source:

Hayashi S, et al. (2023, November 1. Rheumatology (Oxford). Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. https://pubmed.ncbi.nlm.nih.gov/37924201/